Generic Substitution Noninterference Act
Latest action · Nov 1, 2022 Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedApr 7, 2022
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Generic Substitution Noninterference Act
This bill prohibits drug manufacturers from helping or directing health care providers to limit prescriptions to brand-name drugs when generic versions are available. The Federal Trade Commission and states may enforce this bill through civil actions.
Cosponsors 7
Members who signed on, in the order they did. All signed on Apr 7, 2022.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-RI | David N. Cicilline | Original | Apr 7, 2022 |
| D-MD | Jamie Raskin | Original | Apr 7, 2022 |
| D-IL | Janice D. Schakowsky | Original | Apr 7, 2022 |
| D-NY | Jerrold Nadler | Original | Apr 7, 2022 |
| D-CA | Katie Porter | Original | Apr 7, 2022 |
| D-CA | Mark DeSaulnier | Original | Apr 7, 2022 |
| D-VT | Peter Welch | Original | Apr 7, 2022 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Judiciary Committee | Referred Apr 7, 2022 |
| Administrative State, Regulatory Reform, and Antitrust Subcommittee | Referred Nov 1, 2022 |
Actions 3
Everything that happened, newest first.
- Nov 1, 2022Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
- Apr 7, 2022Introduced in House
- Apr 7, 2022Referred to the House Committee on the Judiciary.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 168, no. 62, April 7, 2022, page H4434.
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To prohibit pharmaceutical manufacturers from interfering with therapeutically equivalent or interchangeable substitution decisions by health care providers to limit competition from a generic drug or biosimilar biological product, and for other purposes.
- Short Title(s) as Introduced
- Generic Substitution Noninterference Act
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Apr 7, 2022Introduced in House
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.